• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cryoport to Host Investor Call to Discuss Recent Strategic Agreement and Transformative Transaction Today, March 31, 2025, at 8:30 a.m. ET

    3/31/25 8:09:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYRX alert in real time by email

    NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences sector, today announced that the Company will host an investor call today, Monday, March 31, 2025, at 8:30 a.m. ET, to discuss the Company's recent strategic agreement and transformative transaction, which includes a strategic partnership with the DHL Group (DHL) and DHL's acquisition of CRYOPDP

    Cryoport logo 2024

    The conference call will include remarks by the management team followed by a questions and answers session that will address questions members of the investment community have regarding these recent events. A slide deck will accompany the call.

    Conference Call Information

    Date:

    Monday, March 31, 2025

    Time:

    8:30 a.m. ET, 4:30 PM (UTC+1)

    Dial-in numbers:

    1-800-717-1738 (U.S.), 1-646-307-1865 (International)

    Confirmation code:

    Request the "Cryoport Call" or Conference ID: 1197941

    Live webcast:

    'Investor Relations' section at www.cryoportinc.com or click here.

     

    Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

    The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until April 7, 2025. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1197941#.

    About Cryoport, Inc

    Cryoport, Inc. (NASDAQ:CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.

    Our corporate headquarters, located in Nashville, Tennessee, is complemented by over 50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the Netherlands, Belgium, Portugal, Germany, Japan, Australia, India, and China.

    For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.

    Forward-Looking Statements

    Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the sale of CRYOPDP and the strategic collaboration with DHL, including the potential impact on future revenue and revenue streams.  It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-to-host-investor-call-to-discuss-recent-strategic-agreement-and-transformative-transaction-today-march-31-2025-at-830-am-et-302415562.html

    SOURCE Cryoport, Inc.

    Get the next $CYRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYRX

    DatePrice TargetRatingAnalyst
    3/24/2025$10.00Neutral → Buy
    UBS
    12/19/2024$11.00Buy
    Guggenheim
    12/19/2024$11.00Buy
    Canaccord Genuity
    8/7/2024$20.00 → $8.00Buy → Hold
    Jefferies
    7/31/2024$19.00 → $15.00Neutral → Buy
    B. Riley Securities
    5/3/2024$22.00 → $19.00Buy → Neutral
    B. Riley Securities
    4/4/2024$17.00 → $21.00Buy
    Jefferies
    3/13/2024$19.00 → $18.00Buy
    Needham
    More analyst ratings

    $CYRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cryoport upgraded by UBS with a new price target

      UBS upgraded Cryoport from Neutral to Buy and set a new price target of $10.00

      3/24/25 8:25:01 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Cryoport with a new price target

      Guggenheim initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00

      12/19/24 7:35:39 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Cryoport with a new price target

      Canaccord Genuity initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00

      12/19/24 7:35:29 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CEO Shelton Jerrell exercised 389,720 shares at a strike of $5.00 and sold $2,289,781 worth of shares (339,720 units at $6.74), increasing direct ownership by 6% to 912,419 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      6/20/25 8:15:11 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mandalam Ramkumar sold $75,348 worth of shares (10,712 units at $7.03), decreasing direct ownership by 14% to 66,377 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      6/13/25 7:00:49 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Digital and Tech Officer Zecchini Edward J exercised 75,000 shares at a strike of $3.07 and sold $352,518 worth of shares (51,500 units at $6.84), increasing direct ownership by 35% to 90,411 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      6/10/25 7:28:18 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group

      NASHVILLE, Tenn., June 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leader in temperature-controlled supply chain solutions for the Life Sciences, with a focus on regenerative medicine, today announced the completion of the previously disclosed divestiture of its specialty courier business, CRYOPDP, to DHL Group ("DHL"), one of the world's leading logistics providers, in a transaction that includes cash payments of approximately $200 million to Cryoport. Concurrently, Cryoport and DHL have established a strategic partnership aimed at e

      6/12/25 8:00:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cryoport Reports First Quarter 2025 Financial Results

      Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over yearQ1 2025 revenue from continuing operations of $41.0 million, up 10% year over yearSupporting 711 global clinical trials as of March 31, 2025Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025.  Jerrell Shelton, C

      5/7/25 4:05:00 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025

      NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Wednesday,

      4/24/25 8:30:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    SEC Filings

    See more
    • CryoPort Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cryoport, Inc. (0001124524) (Filer)

      6/13/25 3:55:20 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CryoPort Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cryoport, Inc. (0001124524) (Filer)

      6/10/25 9:00:27 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by CryoPort Inc.

      SD - Cryoport, Inc. (0001124524) (Filer)

      5/30/25 4:31:07 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care